Pneumococcal Vaccine in Lung Cancer: A Literature Review
DOI:
https://doi.org/10.36497/respirsci.v7i1.224Keywords:
conjugate vaccine, pneumococcal vaccine, polysaccharide vaccineAbstract
Streptococcus pneumoniae (S. pneumoniae) is one of the organisms that cause various diseases with a high burden, and pneumonia is one of the major clinical manifestations. The pneumococcal vaccine, as known, provides immunity against S. pneumoniae and consists of two types available in Indonesia: polysaccharide and conjugate vaccines. The polysaccharide vaccine is the 23-valent pneumococcal polysaccharide vaccine (PPSV23), and the conjugate vaccines are the 13-, 15-, and 20-valent pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20). The conjugate vaccine can provide more effective immunity, involving the activation of T cells and memory B cells. By providing effective protection against S. pneumoniae, the pneumococcal vaccine reduces community-acquired pneumonia (CAP) hospitalization and improves overall survival, especially in lung cancer patients who have a higher risk of infection with pneumonia. Aside from the pathological condition, cancer treatment, such as chemotherapy, can alter the immune system, thereby increasing the risk of infection. Therefore, the pneumococcal vaccine is recommended for lung cancer patients. Besides that, knowledge of the pneumococcal vaccine is also essential to optimize lung cancer treatment.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Respiratory Science

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.









